Tel Aviv University researchers have advanced regenerative biotechnology by cultivating human spinal cord stem cells in the lab, progressing toward the first-ever transplant in a paralyzed patient. Following successful animal trials demonstrating unprecedented recovery, this breakthrough opens possibilities of restoring walking ability to individuals with traumatic spinal cord injuries. Led by Prof. Tal Dvir and supported by biotech company Matricelf, the engineered spinal cord mimics native tissue connectivity essential for neural signal transmission disrupted by injury. This novel organ-engineering technology represents a pioneering step in treating spinal cord trauma’s irreversible damage.